Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Asparaginase-Phage P22 Nanoreactors: Toward a Biobetter Development for Acute Lymphoblastic Leukemia Treatment

22 Apr 2021

Abstract excerpt

Asparaginase (ASNase) is a biopharmaceutical for Acute Lymphoblastic Leukemia (ALL) treatment. However, it shows undesirable side effects such as short lifetimes, susceptibility to proteases, and immunogenicity. Here, ASNase encapsidation was genetically directed in bacteriophage P22-based virus-like particles (VLPs) (ASNase-P22 nanoreactors) as a strategy to overcome these challenges. ASNase-P22 was composed of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Lymphoblastic Leukemia research
Share to Biochemical and Molecular Research
Share to CAR-T cell therapy research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33922106
DOI: 10.3390/pharmaceutics13050604

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Asparaginase-Phage P22 Nanoreactors: Toward a Biobetter Development for Acute Lymphoblastic Leukemia TreatmentPMID 33922106Read ↗

Nonclinical Evaluation of Single-Mutant E. coli Asparaginases Obtained by Double-Mutant Deconvolution: Improving Toxicological, Immune and Inflammatory Responses.Semantic proximity Read ↗

Fluorescence-Activated Cell Sorting of Human l-asparaginase Mutant Libraries for Detecting Enzyme Variants with Enhanced Activity.Semantic proximity Read ↗

<em>In Silico</em> Design of a Chimeric Humanized L-Asparaginase.Semantic proximity Read ↗

Mutations in asparaginase II from E. coli and implications for inactivation and PEGylation.Semantic proximity Read ↗

Possible mechanism of metabolic and drug resistance with L-asparaginase therapy in childhood leukaemiaSemantic proximity Read ↗

Cysteine Pegylation of a Mutant L-asparaginase Affords Enhanced Activity and Thermostability. A Comparative Study Against N-terminal Conjugation.Semantic proximity Read ↗

Desirable L-asparaginases for treating cancer and current research trendsSemantic proximity Read ↗

Enhanced Thermostability and Molecular Insights for l -Asparaginase from Bacillus licheniformis via Structure- and Computation-Based Rational DesignSemantic proximity Read ↗

Update on the Use of L-Asparaginase in Infants and Adolescent Patients with Acute Lymphoblastic LeukemiaSemantic proximity Read ↗

Recharacterization of EmAGA, a Potential Candidate for Novel ALL Therapeutics.Semantic proximity Read ↗

Engineering Tk1656, a highly active l-asparaginase from Thermococcus kodakarensis, for enhanced activity and stability.Semantic proximity Read ↗

Biogeneric native and polyethylene glycol-conjugated <i>E. coli</i> asparaginases for treating children with acute lymphoblastic leukaemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.